Dr. Laderoute was the lead discoverer at the Public Health Agency of Canada (PHAC) of human endogenous retrovirus K102 (HERV-K102) as a replication competent, protector foamy retrovirus unique to humans which
may protect against RNA pandemic viruses such as HIV-1 (2007, 2015).
She authored the "New Immunosenescence Paradigm, 2015" and "Clues to Finding Correlates of Risk/Protection for HIV-1 vaccines, 2018" (doi:10.12688/f1000research.11818.2). She was a Brighton Collaboration, Viral Vector Vaccines SAFETY Working Group Member (2008-2015). More recently she authored ‘A Smarter Pandemic Vaccination Strategy’ (submitted) which explains and substantiates how trained (innate) immunity vaccination may be a more suitable approach to taming the pandemic than by adaptive immunity mechanisms. Adaptive immunity which by recognizing virus-specific antigens; may select for variants, increased pathogenesis and the erosion of herd immunity. In contrast, the boosting of trained (innate) immunity can lead to durable sterilizing herd immunity against the alpha and delta variants, needed for ending the pandemic.
Dr. Laderoute is a global expert in trained (innate) immunity involving the production of HERV-K102 protective particles in foamy macrophages and sebocytes (sebaceous glands) in the oral mucosa, and how immunosenescence and/or SARS-CoV-2 can abort trained (innate) immunity leading to increased risks of COVID-19 severity.